NO20006087L - Fremgangsmåter for å öke nivåer av acetylcholin - Google Patents

Fremgangsmåter for å öke nivåer av acetylcholin

Info

Publication number
NO20006087L
NO20006087L NO20006087A NO20006087A NO20006087L NO 20006087 L NO20006087 L NO 20006087L NO 20006087 A NO20006087 A NO 20006087A NO 20006087 A NO20006087 A NO 20006087A NO 20006087 L NO20006087 L NO 20006087L
Authority
NO
Norway
Prior art keywords
acetylcholine
methods
increase levels
compound
formula
Prior art date
Application number
NO20006087A
Other languages
English (en)
Other versions
NO20006087D0 (no
Inventor
Henry Uhlman Bryant
Michele Anette Glinn
Steven Mark Paus
Xin Wu
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20006087D0 publication Critical patent/NO20006087D0/no
Publication of NO20006087L publication Critical patent/NO20006087L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
    • A61K31/621—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate having the hydroxy group in position 2 esterified, e.g. benorylate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

Den foreliggende oppfinnelsen vedrører en fremgangsmåte for å øke nivåer av acetylcholin i pattedyr omfattende å administrere til et pattedyr som har behov for dette, en effektiv mengde av en forbindelse med formel (I), og eventuelt en AChE hemmer. ORJ Oppfinnelsen omfatter andvendelse av forbindelse med formel I for fremstilling av et medikament til behandling av alzheimers sykdom.
NO20006087A 1998-06-16 2000-11-30 Fremgangsmåter for å öke nivåer av acetylcholin NO20006087L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8948998P 1998-06-16 1998-06-16
PCT/US1999/012525 WO1999065489A1 (en) 1998-06-16 1999-06-04 Methods for increasing levels of acetylcholine

Publications (2)

Publication Number Publication Date
NO20006087D0 NO20006087D0 (no) 2000-11-30
NO20006087L true NO20006087L (no) 2000-11-30

Family

ID=22217929

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20006087A NO20006087L (no) 1998-06-16 2000-11-30 Fremgangsmåter for å öke nivåer av acetylcholin

Country Status (18)

Country Link
US (1) US6395719B1 (no)
EP (1) EP0970695A1 (no)
JP (1) JP2002518329A (no)
KR (1) KR20010052891A (no)
CN (1) CN1305377A (no)
AU (1) AU751158B2 (no)
BR (1) BR9911220A (no)
CA (1) CA2335295A1 (no)
EA (1) EA200100039A1 (no)
HR (1) HRP20000862A2 (no)
HU (1) HUP0102506A3 (no)
IL (1) IL139015A0 (no)
NO (1) NO20006087L (no)
PL (1) PL344785A1 (no)
SK (1) SK18792000A3 (no)
TR (1) TR200003704T2 (no)
WO (1) WO1999065489A1 (no)
ZA (1) ZA200005887B (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288108B1 (en) 1998-06-16 2001-09-11 Eli Lilly And Company Methods for increasing levels of acetylcholine
JP2002518329A (ja) 1998-06-16 2002-06-25 イーライ・リリー・アンド・カンパニー アセチルコリンレベルを増加させる方法
EP0976404A3 (en) * 1998-07-30 2001-06-27 Pfizer Products Inc. A pharmaceutical composition for the prevention and treatment of diseases of cognitive dysfunction in a mammal
CA2552221A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Donepezil formulations
GB0511003D0 (en) * 2005-05-28 2005-07-06 Univ Cardiff Screening and treatment of alzheimer's disease

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0002097B1 (en) 1977-08-22 1981-08-05 Imperial Chemical Industries Plc Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them
TW366342B (en) 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5554601A (en) 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
US6489355B2 (en) 1993-12-01 2002-12-03 Eli Lilly And Company Methods of inhibiting the effects of amyloidogenic proteins
US5552415A (en) 1993-12-21 1996-09-03 Eli Lilly And Company Method of inhibiting Alzheimer's Disease
JPH09507071A (ja) 1993-12-21 1997-07-15 イーライ・リリー・アンド・カンパニー アミロイド原性ペプチドに関連した状態を治療又は予防する方法
US5441965A (en) 1993-12-21 1995-08-15 Eli Lilly And Company Methods of inhibiting thrombin
US5578613A (en) 1993-12-21 1996-11-26 Eli Lilly And Company Methods for inhibiting weight gain or inducing weight loss
US5534526A (en) 1993-12-21 1996-07-09 Eli Lilly And Company Methods for inhibiting vasomotor symptoms and attending psychological disturbances surrounding post-menopausal syndrome
US5462950A (en) 1993-12-21 1995-10-31 Eli Lilly And Company Methods of treating menstrual symptoms and compositions therefore
US5389670A (en) 1993-12-21 1995-02-14 Eli Lilly Company Methods of inhibiting the symptoms of premenstrual syndrome/late luteal phase dysphoric disorder
US5604248A (en) 1994-05-05 1997-02-18 Eli Lilly And Company Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs
US5512296A (en) 1994-08-22 1996-04-30 Eli Lilly And Company Methods for inhibiting neuronal damage
US5510357A (en) 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
AR003930A1 (es) 1995-02-28 1998-09-30 Lilly Co Eli Procedimiento para preparar compuestos de 2-fenil-3-fenoxi o feniltio-benzotiofeno y sales farmaceuticamente aceptables, compuestos intermediarios de aplicación exclusiva en dicho procedimiento y metodo para preparar los compuestos intermediarios mencionados
US5731342A (en) * 1996-02-22 1998-03-24 Eli Lilly And Company Benzothiophenes, formulations containing same, and methods
IL120269A0 (en) 1996-02-28 1997-06-10 Pfizer 1,1,2-triphenylbut-1-ene derivatives for treating Alzheimer's disease
ES2188946T3 (es) 1996-06-07 2003-07-01 Eisai Co Ltd Polimorfos de clorhidrato de donepecil y proceso de fabricacion de los mismos.
ZA982877B (en) 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.
SK18812000A3 (sk) 1998-06-16 2002-01-07 Eli Lilly And Company Spôsoby zvyšovania hladín acetylcholínu
JP2002518329A (ja) 1998-06-16 2002-06-25 イーライ・リリー・アンド・カンパニー アセチルコリンレベルを増加させる方法

Also Published As

Publication number Publication date
ZA200005887B (en) 2002-07-22
AU4333899A (en) 2000-01-05
AU751158B2 (en) 2002-08-08
EP0970695A1 (en) 2000-01-12
TR200003704T2 (tr) 2001-06-21
US6395719B1 (en) 2002-05-28
PL344785A1 (en) 2001-11-19
HRP20000862A2 (en) 2001-10-31
SK18792000A3 (sk) 2001-07-10
WO1999065489A1 (en) 1999-12-23
BR9911220A (pt) 2001-03-06
NO20006087D0 (no) 2000-11-30
HUP0102506A2 (hu) 2002-01-28
CN1305377A (zh) 2001-07-25
IL139015A0 (en) 2001-11-25
CA2335295A1 (en) 1999-12-23
EA200100039A1 (ru) 2001-06-25
JP2002518329A (ja) 2002-06-25
HUP0102506A3 (en) 2003-01-28
KR20010052891A (ko) 2001-06-25

Similar Documents

Publication Publication Date Title
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
NO961326D0 (no) Inhibitorer av
NO962568L (no) Anvendelse av PLA2 inhibitorer som behandling for Alzheimers sykdom
ATE320803T1 (de) Verfahren zur behandlung von alzheimerschen krankheit
EA199900490A1 (ru) СПОСОБЫ И СОЕДИНЕНИЯ ДЛЯ ИНГИБИРОВАНИЯ ВЫДЕЛЕНИЯ β-АМИЛОИДНОГО ПЕПТИДА И/ИЛИ ЕГО СИНТЕЗА
WO2003104273A3 (en) Therapeutic epitopes and uses thereof
EA200400162A1 (ru) N-(3-амино-2-гидроксипропил)замещенные алкиламидные соединения
EA200201247A1 (ru) Соединения для лечения болезни альцгеймера
BR0308243A (pt) Composto, formulação farmacêutica, e, métodos de tratar diabetes, doença de alzheimer, e de inibir gsk-3 em um mamìfero
LU91926I2 (fr) Belimumab et ses dérivés pharmaceutiquement acceptables (Benlysta®)
EA199900778A1 (ru) ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ И ИХ ИСПОЛЬЗОВАНИЕ ДЛЯ ИНГИБИРОВАНИЯ β-АМИЛОИДНОГО ПЕПТИДА
WO2002002518A3 (en) Compounds to treat alzheimer&#39;s disease
FI934223A0 (fi) Heterocykliscykliska aminderivat
MXPA03010843A (es) Uso de derivados con azetidinona en el tratamiento de enfermedad de alzheimer.
WO2002002520A8 (en) Compounds to treat alzheimer&#39;s disease
MXPA04003245A (es) Hidroxipropilaminas.
WO2001058476A3 (en) Methods and compositions for treatment of alzheimer&#39;s disease by enhancing plasmin or plasmin-like activity
NO970161L (no) Triazolforbindelser og anvendelse derav
MXPA04002785A (es) Aminas sustituidas para tratamiento de enfermedad de alzheimer.
MXPA04000338A (es) Diamindioles para tratamiento de enfermedad de alzheimer.
DE69735442D1 (de) Antidiabetische mittel
BR9712792A (pt) Inibidores de metaloprotease bidentada.
MXPA03011521A (es) Aminadioles para tratamiento de enfermedad de alzheimer.
BR0210392A (pt) Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto
BR0011728A (pt) Método de inibir a agregação de proteìna amilóide e imagem de depósitos de amilóide

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application